KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Enterprise Value (2017 - 2025)

Aquestive Therapeutics has reported Enterprise Value over the past 9 years, most recently at -$121.2 million for Q4 2025.

  • Quarterly results put Enterprise Value at -$121.2 million for Q4 2025, down 69.36% from a year ago — trailing twelve months through Dec 2025 was -$121.2 million (down 69.36% YoY), and the annual figure for FY2025 was -$121.2 million, down 69.36%.
  • Enterprise Value for Q4 2025 was -$121.2 million at Aquestive Therapeutics, up from -$129.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for AQST hit a ceiling of -$14.7 million in Q1 2022 and a floor of -$129.1 million in Q3 2025.
  • Median Enterprise Value over the past 5 years was -$29.6 million (2021), compared with a mean of -$50.6 million.
  • Biggest five-year swings in Enterprise Value: soared 48.31% in 2022 and later plummeted 300.56% in 2024.
  • Aquestive Therapeutics' Enterprise Value stood at -$28.0 million in 2021, then increased by 2.68% to -$27.3 million in 2022, then rose by 12.47% to -$23.9 million in 2023, then tumbled by 199.71% to -$71.5 million in 2024, then crashed by 69.36% to -$121.2 million in 2025.
  • The last three reported values for Enterprise Value were -$121.2 million (Q4 2025), -$129.1 million (Q3 2025), and -$60.5 million (Q2 2025) per Business Quant data.